2m 2m 2m 2m 2m 2m 2m
CAMP4 THERAP (CAMP)
NASDAQ
$4.19+$0.01 (+0.36%)
Price as of Jun 03, 2026 4:10 PM EDT- $228.0MMarket Cap
- 105.15%1-Year Change
- BiotechnologyIndustry
CAMP4 THERAP (CAMP)
$4.19+$0.01 (+0.36%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 3.5M +436.50% | 652,000 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 3.5M +436.50% | 652,000 N/A | |
Sales and Marketing Expense | 659,000 +8.39% | 608,000 N/A | |
Research and Development Expense | -38.2M -1.58% | -38.8M N/A | |
Depreciation and Amortization Expense | 1.6M -3.36% | 1.7M N/A | |
Total Operating Expenses | 56.1M +4.30% | 53.7M N/A | |
Operating Profit | -52.6M -1.00% | -53.1M N/A | |
Interest Income | 2.2M +63.46% | 1.3M N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 2.2M +63.46% | 1.3M N/A | |
Total Nonoperating Income and Expense | -27.8M -2,247.11% | 1.3M N/A | |
Income before Taxes | -52.6M -1.00% | -53.1M N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | 500,000 N/A | N/A N/A | |
Net Income | -80.4M +55.25% | -51.8M N/A | |
Net Income from Continuing Operations Applicable to Common | -80.4M +55.25% | -51.8M N/A | |
Basic EPS and Net Income | -2.65 -76.00% | -11.04 N/A | |
Diluted EPS and Net Income | -2.65 -76.00% | -11.04 N/A | |
Basic Weighted Average Shares | 30.4M +547.76% | 4.7M N/A | |
Diluted Weighted Average Shares | 30.4M +547.76% | 4.7M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 109.5M +71.02% | 64.0M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 109.5M +71.02% | 64.0M N/A | |
Total Current Assets | 114.1M +71.87% | 66.4M N/A | |
Accumulated Depreciation | 7.7M +24.33% | 6.2M N/A | |
Property and Plant and Equipment and Net | 2.3M -39.37% | 3.9M N/A | |
Total Long-Term Assets | 83,000 -97.85% | 3.9M N/A | |
Total Assets | 117.8M +50.44% | 78.3M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 15.5M +61.64% | 9.6M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 29,000 +1,350.00% | 2,000 N/A | |
Total Liabilities | 70.1M +362.34% | 15.2M N/A | |
Retained Earnings | -292.2M +37.97% | -211.8M N/A | |
Total Stockholders Equity | 47.7M -24.45% | 63.1M N/A | |
Total Shares Outstanding | 51.9M +157.64% | 20.1M N/A | |
Cash Flow | |||
Cash from Operating Activities | -29.6M -35.14% | -45.6M N/A | |
Capital Expenditures | 279,000 -36.73% | 441,000 N/A | |
Cash from Investing Activities | -243,000 -44.90% | -441,000 N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 75.9M +5.90% | 71.7M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | -1,502.43% N/A | N/A N/A | |
Return on Assets | -82.00% N/A | N/A N/A | |
Return on Equity | -145.07% N/A | N/A N/A | |
Revenue Growth | 436.50% N/A | N/A N/A | |
Current Ratio | 7.35 N/A | N/A N/A | |
Cash Ratio | 7.06 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow